Cloud P. Paweletz

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• PTPN2 inhibition unleashes response to STING agonism in head and neck squamous cell cancer

  Nature Communications · 2026-05-02

• Abstract 243: DNA fiber-based replication phenotypes distinguish WEE1-inhibitor response in high-grade endometrial cancer patient-derived organoids (PDOs) treated with azenosertib.

  Cancer Research · 2026-04-03

• Abstract 2830: Immunomodulatory response in Dato-DXd-treated non-small cell lung cancer patient-derived organotypic tumor spheroids (pDOTS)

  Cancer Research · 2026-04-03

• Table S3 from Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer

  2026-03-16

• Figure S2 from Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer

  2026-03-16

• Figure S1 from Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer

  2026-03-16

• Figure S4 from Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer

  2026-03-16

• Figure S3 from Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer

  2026-03-16

• Table S2 from Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer

  2026-03-16

• Figure S5 from Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer

  2026-03-16

• Table S1 from Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer

  2026-03-16

• Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancer

  Cancer Cell · 2026-03-05 · 4 citations

• Abstract A038: Targeting RAS in gynecologic cancers

  Cancer Research · 2026-03-05

• Aging-associated differences in mammary tumor–initiating populations and immune evasion pathways in breast cancer

  Proceedings of the National Academy of Sciences · 2026-02-20

• Data from A Phase Ib Study of Sapacitabine and Olaparib in Patients with <i>BRCA1/2-</i>Mutated Metastatic Breast Cancer

  2026-02-04

• Supplementary Data1 from A Phase Ib Study of Sapacitabine and Olaparib in Patients with <i>BRCA1/2-</i>Mutated Metastatic Breast Cancer

  2026-02-04

• EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy

  JCI Insight · 2026-01-22

• Drug-tolerant persisters and immunotherapy persister cells exhibit cross-resistance and share common survival mechanisms

  Cell Death and Differentiation · 2025-12-26

• A Phase Ib Study of Sapacitabine and Olaparib in Patients with <i>BRCA1/2-</i> Mutated Metastatic Breast Cancer

  Clinical Cancer Research · 2025-12-03

• Cancers modulate p53 truncal neoantigen display to evade T cell detectionPreprint

  bioRxiv (Cold Spring Harbor Laboratory) · 2025-11-30